Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amitkumar Mehta

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Nature Communications|November 5, 2025
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphomaSunandini Sharma, Roshia Ali, Alyssa Bouska, et al.
Journal of Hematology & Oncology|December 16, 2023
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma ConsortiumJulie M Vose, Kai Fu, Lu Wang, et al.
Nature Communications|May 24, 2018
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical modelsSamuel Y Ng, Noriaki Yoshida, Amanda L Christie, et al.
Blood Advances|October 24, 2023
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphomaJames N Gerson, Elizabeth Handorf, Diego Villa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2019
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab EraJames N Gerson, Elizabeth Handorf, Diego Villa, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Cancer Journal|April 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapyYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Nature Communications|November 5, 2025
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphomaSunandini Sharma, Roshia Ali, Alyssa Bouska, et al.
Journal of Hematology & Oncology|December 16, 2023
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma ConsortiumJulie M Vose, Kai Fu, Lu Wang, et al.
Nature Communications|May 24, 2018
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical modelsSamuel Y Ng, Noriaki Yoshida, Amanda L Christie, et al.
Blood Advances|October 24, 2023
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphomaJames N Gerson, Elizabeth Handorf, Diego Villa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2019
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab EraJames N Gerson, Elizabeth Handorf, Diego Villa, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Cancer Journal|April 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapyYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 8